Search clinical trials for: AZD9819

Total 135 results

AstraZeneca

Recruiting

Study of AZD9829 in CD123+ Hematological Malignancies

Hematological Malignancies

United States, Spain, Korea, Republic of, Italy, Japan, Taiwan, Australia, Germany, China
AstraZeneca

Completed

Assessment of Safety, Tolerability and Blood Concentrations of Single Doses of AZD3839 in Healthy Volunteers

Healthy Volunteers | Alzheimer's Disease | Tolerability | Safety | Blood Concentration

United Kingdom
AstraZeneca

Completed

Single Centre, Double-blind, Single and Multiple Ascending Inhaled Doses of AZD9819 in Healthy Subjects

Healthy Volunteers | Tolerability | Safety

United Kingdom
AstraZeneca
Quotient Sciences

Completed

A Study to Assess the Rel Bioavailability, Food Effect and Absolute Bioavailability on the Pharmacokinetics of AZD9833

Healthy Volunteers

United Kingdom
AstraZeneca

Active, not recruiting

A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer

ER+ HER2- Advanced Breast Cancer

Japan
Samsung Medical Center
AstraZeneca

Terminated

AZD 2811 Monotherapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N3]

Small Cell Lung Cancer

Korea, Republic of
AstraZeneca

Completed

Study to Assess the Metabolism, Excretion and Pharmacokinetics of [14C]AZD1981 in Healthy Male Volunteers (ADME)

Healthy
AstraZeneca

Completed

AZD1419 Ph2a Study (INCONTRO)

Asthma

Denmark, Sweden, Hungary, Poland
AstraZeneca

Completed

Study to Assess the Efficacy and Safety of AZD1981 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (Columbus)

Moderate to Severe COPD

Sweden, Bulgaria, Poland, Denmark, Slovakia
AstraZeneca

Completed

Tolerability/Safety and Efficacy of Inhaled AZD4818 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (TOP)

Chronic Obstructive Pulmonary Disease (COPD)

Sweden, Denmark, Finland, Netherlands, Norway
AstraZeneca

Completed

Single and Multiple Ascending Doses of AZD1981 in Japan (JSAD/JMAD)

Healthy

United Kingdom
AstraZeneca

Completed

A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors.

Advanced Solid Tumours

United States
AstraZeneca

Completed

14729-D9831C00002- 1 Month Biopsy Study (Biopsy)

Chronic Obstructive Pulmonary Disease

United Kingdom, Germany, Netherlands
AstraZeneca

Completed

One Month Dose Response Study of AZD1981 in Asthma Patients Uncontrolled on Inhaled Steroids (OLIVE)

Asthma

Poland, Argentina, Brazil, Costa Rica
AstraZeneca

Completed

Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients (Sweapea)

Asthma Patients

United States, Mexico, Russian Federation, South Africa, Romania, Ukraine, Japan, Argentina, Slovakia, Brazil
AstraZeneca

Completed

A Drug-drug Interaction Study to Investigate the Effects of AZD1981 on the Metabolism and Pharmacodynamics of Oral Contraceptives

Oral Contraceptives

Sweden
AstraZeneca

Completed

Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female Subjects

Hepatic Impairment

United States, Bulgaria, Slovakia
AstraZeneca

Completed

Safety, Tolerability and Pharmacokinetics of Inhaled Doses of AZD4818 in Healthy Japanese Male Volunteers

Healthy

Japan
AstraZeneca
Parexel

Terminated

A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of AZD9898

Asthma

United Kingdom
AstraZeneca

Completed

A Bioavailability Study Comparing 3 Different AZD1981 Tablets

Healthy

Sweden
AstraZeneca

Completed

A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer (SERENA-3)

HER2-negative Breast Cancer

Mexico, United Kingdom, Georgia
AstraZeneca

Active, not recruiting

Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer. (SERENA-1)

ER+ HER2- Advanced Breast Cancer

United States, Spain, United Kingdom
AstraZeneca

Completed

AZD1981 Bioavailability Study of Intravenous (IV) and Oral Formulations

Healthy | Postmenopausal | Surgically Sterile Women

Sweden
AstraZeneca

Active, not recruiting

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

Advanced Non Small Cell Lung Cancer

Canada, Poland, Taiwan, United States, Korea, Republic of, Japan, Russian Federation, Ukraine
AstraZeneca

Completed

A Phase I, Open-label Study to Assess Bioavailability of a Single Oral Dose of AZD9291 vs an IV Dose of [14C]AZD9291

Oncology

United Kingdom
Johns Hopkins University
AstraZeneca

Completed

Efficacy and Safety of Chemoattractant Receptor-homologous Molecule Expressed on T Helper Type 2 (CRTh2) Antagonist AZD1981 in Chronic Idiopathic Urticaria (CIU) Antihistamines

Chronic Idiopathic Urticaria

United States
AstraZeneca

Completed

Pharmacokinetics in Adolescents (PEAK)

Asthma

Sweden
AstraZeneca

Active, not recruiting

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy. (ADAURA)

Stage IB-IIIA Non-small Cell Lung Carcinoma

United States, Italy, Netherlands, Belgium, Canada, Poland, Romania, Taiwan, Thailand, Vietnam, France, Brazil, Hungary, Japan, Russian Federation, Turkey, China, Korea, Republic of, Germany, Hong Kong, Spain, Australia, Israel, Ukraine, Swed...
AstraZeneca

Completed

AZD9833 China PK Study (AZD9833)

ER+, HER2-, Metastatic Breast Cancer

China
Istituto Auxologico Italiano
University of Florence; Apnimed Inc.; VIS Ethic Research Srl; STM Pharma PRO srl

Recruiting

Study of AD981 Versus Placebo in Obesity Hypoventilation Syndrome (ATOHS)

Obesity Hypoventilation Syndrome (OHS)

Italy
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Japanese Men

Coronary Artery Disease

United States
AstraZeneca

Recruiting

A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19 (ARTEMIS-C)

COVID-19 | SARS-CoV-2 Infection

United States
AstraZeneca

Completed

Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain Metastases (ODIN-BM)

Non-small Cell Lung Cancer

Sweden
AstraZeneca

Completed

A Drug-Drug Interaction Study to Study the Effect of AZD1981 on Warfarin

Pharmakokinetic

Sweden
AstraZeneca

Completed

Phase I, Study in Chinese NSCLC Patients (AURAChinaPK)

Carcinoma, Non-Small-Cell Lung With EGFR Mutation Positive

China
AstraZeneca
Quotient Sciences

Completed

A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]AZD9833

ER-positive, HER2-negative Breast Cancer

United Kingdom
AstraZeneca

Completed

Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer

Advanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung Cancer

France, Korea, Republic of, United Kingdom, Spain
AstraZeneca

Completed

Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment

Solid Tumours

United States, Spain, Belgium, France, Korea, Republic of, United Kingdom
Se-Hoon Lee

Terminated

AZD2811 and Durvalumab (MEDI4736) Combination Therapy in Relapsed Small Cell Lung Cancer (SUKSES-N5)

SCLC, Recurrent

Korea, Republic of
AstraZeneca
TigerMed

Completed

T790M Plasma Testing Methodology Comparison and Clinical Validation (ADELOS)

Lung Cancer

China
Shandong Cancer Hospital and Institute
AstraZeneca

Unknown

Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M

Nonsmall Cell Lung Cancer | Brain Metastases | EGFR-TKI Resistant Mutation | AZD9291
AstraZeneca

Completed

To Investigate the Effects of AZD1981 on the QT Interval

Asthma

United Kingdom
AstraZeneca

Completed

Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults (AZD2816)

COVID-19 | SARS-CoV-2

United Kingdom, Brazil, South Africa, Poland
AstraZeneca

Completed

Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers

Healthy Volunteer

United States
Samsung Medical Center

Active, not recruiting

Study of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and/or LMS

Non-Small Cell Lung Cancer With EGFR T790M Mutation | With Brain and/or Leptomeningeal Metastasis | Failed Tyrosine Kinase Inhibitors

Korea, Republic of
Chonnam National University Hospital

Completed

Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA (LiquidLung-O)

Lung Neoplasms | EGFR Gene Mutations

Korea, Republic of
Dana-Farber Cancer Institute
AstraZeneca

Recruiting

Osimertinib In EGFR Mutant Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
Shaare Zedek Medical Center
AstraZeneca

Recruiting

Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLC

Lung Cancer, Non-small Cell

Israel
AstraZeneca

No longer available

AZD9291 US Expanded Access Program

EGFR T790M Mutation Positive NSCLC

United States
Tianjin Medical University Cancer Institute and...

Recruiting

Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)

NSCLC, Stage I

China

Search clinical trials for: AZD9819

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Brazil

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations